CN104024244B - 杂环化合物、含有所述化合物的药物及其用途和其制备方法 - Google Patents

杂环化合物、含有所述化合物的药物及其用途和其制备方法 Download PDF

Info

Publication number
CN104024244B
CN104024244B CN201280065806.8A CN201280065806A CN104024244B CN 104024244 B CN104024244 B CN 104024244B CN 201280065806 A CN201280065806 A CN 201280065806A CN 104024244 B CN104024244 B CN 104024244B
Authority
CN
China
Prior art keywords
alkyl
hydrogen
phenyl
amino
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280065806.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104024244A (zh
Inventor
A.赫克尔
S.弗拉蒂尼
D.哈姆普里克特
J.克雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to CN201610685839.2A priority Critical patent/CN106279110B/zh
Publication of CN104024244A publication Critical patent/CN104024244A/zh
Application granted granted Critical
Publication of CN104024244B publication Critical patent/CN104024244B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Hydrogenated Pyridines (AREA)
CN201280065806.8A 2011-11-02 2012-10-29 杂环化合物、含有所述化合物的药物及其用途和其制备方法 Active CN104024244B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610685839.2A CN106279110B (zh) 2011-11-02 2012-10-29 杂环化合物、含有所述化合物的药物及其用途和其制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02
EP11187553.0 2011-11-02
PCT/EP2012/071352 WO2013064450A1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610685839.2A Division CN106279110B (zh) 2011-11-02 2012-10-29 杂环化合物、含有所述化合物的药物及其用途和其制备方法

Publications (2)

Publication Number Publication Date
CN104024244A CN104024244A (zh) 2014-09-03
CN104024244B true CN104024244B (zh) 2016-09-14

Family

ID=47073464

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610685839.2A Active CN106279110B (zh) 2011-11-02 2012-10-29 杂环化合物、含有所述化合物的药物及其用途和其制备方法
CN201280065806.8A Active CN104024244B (zh) 2011-11-02 2012-10-29 杂环化合物、含有所述化合物的药物及其用途和其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610685839.2A Active CN106279110B (zh) 2011-11-02 2012-10-29 杂环化合物、含有所述化合物的药物及其用途和其制备方法

Country Status (34)

Country Link
US (4) US8759349B2 (enExample)
EP (1) EP2773633B1 (enExample)
JP (1) JP6091513B2 (enExample)
KR (1) KR102006612B1 (enExample)
CN (2) CN106279110B (enExample)
AP (1) AP2014007670A0 (enExample)
AU (1) AU2012331274B2 (enExample)
BR (1) BR112014010583A2 (enExample)
CA (1) CA2854217C (enExample)
CL (1) CL2014001047A1 (enExample)
CO (1) CO6940429A2 (enExample)
CY (1) CY1120974T1 (enExample)
DK (1) DK2773633T3 (enExample)
EA (1) EA025158B9 (enExample)
EC (1) ECSP14001929A (enExample)
ES (1) ES2645744T3 (enExample)
GE (1) GEP20186880B (enExample)
HR (1) HRP20171614T1 (enExample)
HU (1) HUE034929T2 (enExample)
IL (1) IL232035A (enExample)
LT (1) LT2773633T (enExample)
ME (1) ME02905B (enExample)
MX (1) MX348522B (enExample)
NO (1) NO2773633T3 (enExample)
PE (1) PE20141607A1 (enExample)
PH (1) PH12014500970B1 (enExample)
PL (1) PL2773633T3 (enExample)
PT (1) PT2773633T (enExample)
RS (1) RS56498B1 (enExample)
SG (1) SG11201401907TA (enExample)
SI (1) SI2773633T1 (enExample)
TN (1) TN2014000180A1 (enExample)
UA (1) UA115868C2 (enExample)
WO (1) WO2013064450A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279110B (zh) * 2011-11-02 2019-12-10 勃林格殷格翰国际有限公司 杂环化合物、含有所述化合物的药物及其用途和其制备方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2016525508A (ja) * 2013-07-02 2016-08-25 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 嚢胞性線維症の処置のための化合物
EP3019492B1 (en) * 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
MX373603B (es) * 2014-10-24 2020-05-26 Ono Pharmaceutical Co Activador de canales de kcnq2-5.
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135557A1 (en) * 2007-05-07 2008-11-13 Novartis Ag Organic compounds
WO2009138378A1 (en) * 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (enExample) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
EP1196396B1 (en) 1999-07-19 2008-03-26 University Of North Carolina At Chapel Hill Pharmacologically active compounds with two covalently linked active principles (sodium channnel blocker/p2y2 receptor agonist) for the treatment of mucosal surfaces
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
JP2008510702A (ja) 2004-08-18 2008-04-10 マイケル・アール・ジョンソン 脂肪族アミド及びエステルピラジノイルグアニジンナトリウムチャネル遮断薬
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008013557A1 (en) * 2006-07-24 2008-01-31 International Stem Cell Corporation Synthetic cornea from retinal stem cells
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2839709C (en) 2011-06-27 2020-01-14 Parion Sciences, Inc. A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
CN104024231A (zh) 2011-11-02 2014-09-03 勃林格殷格翰国际有限公司 制备酰基胍和酰基硫脲化合物的新方法
PT2773633T (pt) * 2011-11-02 2017-11-14 Boehringer Ingelheim Int Compostos heterocíclicos, medicamentos contendo os referidos compostos, sua utilização e processos para a sua preparação

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135557A1 (en) * 2007-05-07 2008-11-13 Novartis Ag Organic compounds
WO2009138378A1 (en) * 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design, Synthesis, and Structure-Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers: Drugs for Cystic Fibrosis and Chronic Bronchitis;Andrew J. Hirsh, et al.;《J. MeD. Chem.》;20060613;第49卷;第4098-4115页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279110B (zh) * 2011-11-02 2019-12-10 勃林格殷格翰国际有限公司 杂环化合物、含有所述化合物的药物及其用途和其制备方法

Also Published As

Publication number Publication date
KR102006612B1 (ko) 2019-08-02
IL232035A (en) 2017-05-29
PH12014500970B1 (en) 2017-10-06
GEP20186880B (en) 2018-07-25
AP2014007670A0 (en) 2014-05-31
US20180194747A1 (en) 2018-07-12
HK1196819A1 (zh) 2014-12-24
EP2773633A1 (en) 2014-09-10
WO2013064450A1 (en) 2013-05-10
JP6091513B2 (ja) 2017-03-08
AU2012331274A1 (en) 2014-04-03
UA115868C2 (uk) 2018-01-10
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
NO2773633T3 (enExample) 2017-12-30
US20140228374A1 (en) 2014-08-14
DK2773633T3 (da) 2017-11-13
CN106279110B (zh) 2019-12-10
EA025158B1 (ru) 2016-11-30
EA201400521A1 (ru) 2014-09-30
MX348522B (es) 2017-06-16
US20130109697A1 (en) 2013-05-02
SG11201401907TA (en) 2014-05-29
PE20141607A1 (es) 2014-11-23
ECSP14001929A (es) 2015-11-30
KR20140085498A (ko) 2014-07-07
EP2773633B1 (en) 2017-08-02
BR112014010583A2 (pt) 2020-04-22
PT2773633T (pt) 2017-11-14
AU2012331274B2 (en) 2017-06-08
PH12014500970A1 (en) 2014-06-09
CY1120974T1 (el) 2019-12-11
US9920035B2 (en) 2018-03-20
JP2014534222A (ja) 2014-12-18
CO6940429A2 (es) 2014-05-09
ES2645744T3 (es) 2017-12-07
RS56498B1 (sr) 2018-01-31
CA2854217C (en) 2019-12-31
LT2773633T (lt) 2017-11-10
TN2014000180A1 (en) 2015-09-30
US8759349B2 (en) 2014-06-24
IL232035A0 (en) 2014-05-28
CN106279110A (zh) 2017-01-04
CA2854217A1 (en) 2013-05-10
ME02905B (me) 2018-10-20
CL2014001047A1 (es) 2014-11-07
SI2773633T1 (sl) 2017-11-30
US20150336933A1 (en) 2015-11-26
MX2014005166A (es) 2014-05-28
CN104024244A (zh) 2014-09-03
HUE034929T2 (en) 2018-03-28
HRP20171614T1 (hr) 2017-12-01
EA025158B9 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
CN104024244B (zh) 杂环化合物、含有所述化合物的药物及其用途和其制备方法
JP6072920B2 (ja) 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法
JP6110872B2 (ja) ヘテロ環式化合物、前記化合物を含む薬物、その使用及びその調製方法
JP5021624B2 (ja) 炎症性疾患の治療用新規化合物
JP6204977B2 (ja) 三級アミン、前記アミンを含む薬物、その使用及びその調製方法
HK1232876A1 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
HK1196819B (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
OA16887A (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof.
NZ622469B2 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
HK1114855A (en) Novel compounds for treating inflammatory diseases
HK1115018A (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1196819

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1196819

Country of ref document: HK